Jasper Therapeutics, Inc. · NASDAQ:JSPR
Jasper Therapeutics — Investor Presentation (March 2022)
8 slides from Jasper Therapeutics's investor presentation, Mar 16, 2022
Slide 1: Transforming the Field of Hematopoietic Stem Cell Therapies
Transforming the Field of Hematopoietic Stem Cell Therapies Nasdaq: JSPR March 2022
Slide 2: Safe Harbor Statement
2 JSP191 is an investigative drug and is not approved for any indication Safe Harbor Statement Forward - Looking Statements This investor presentation and any accompanying oral presentation (together, this “Presentation”) contain forward - looking statements . All statements other than statements of
Slide 3: Jasper Highlights
3 JSP191 is an investigative drug and is not approved for any indication • Science targeting the central role of stem cells to cure a growing number of fatal diseases • JSP191: First in class Phase 1/2 anti - CD117 antibody conditioning agent • Clinical data in SCID & AML/ MDS transplant populations
Slide 4: JSP191 stem cell conditioning for AML/MDS and SCID transplant patients
4 JSP191 is an investigative drug and is not approved for any indication JSP191 stem cell conditioning for AML/ MDS and SCID transplant patients JSP191 blocks CD117 (Stem Cell Factor Receptor) leading to hematopoietic stem and progenitor cell depletion • Synergistic with other stem cell targeting me
Slide 5: New therapeutic approach for disease modification in lower risk MDS patients
5 JSP191 is an investigative drug and is not approved for any indication New therapeutic approach for disease modification in lower risk MDS patients JSP191 depletes diseased MDS cells in a mouse xenograft model 1 JSP191 targets diseased MDS to potentially restore normal hematopoiesis % depletion of
Slide 6: Jasper mRNA technology for transient modification of gene therapy and stem cell grafts
6 JSP191 is an investigative drug and is not approved for any indication Jasper mRNA technology for transient modification of gene therapy and stem cell grafts Increasing stem cell proliferation, homing and modifying immune profile mRNA transient modification » Increased engraftment of gene therapy
Slide 7: Jasper's Expanding Pipeline
7 JSP191 is an investigative drug and is not approved for any indication Indication R&D Partner Research Preclinical Clinical Milestones JSP191 Conditioning Sponsored Studies AML/MDS • Updated Phase Ib data (TCT Meeting on April 26 th ) • Pivotal trial initiation by Q1 2023 SCID • Mid 2023 Phase I/I
Slide 8: Transforming the Field of Hematopoietic Stem Cell Therapies
Transforming the Field of Hematopoietic Stem Cell Therapies Nasdaq: JSPR March 2022
Jasper Therapeutics — Investor Presentation (March 2022) on 6ix